James Rohack, the association’s president, NPR asks What’s going on? Rohack says, In the past some have painted the AMA as a business of ‘no.’ We oppose, we oppose, we oppose. In the 21st century, I believe the AMA reflects a business that looks to improve care and match our mission of helping doctors help patients . This content can be republished with kind permission from our close friends at The Kaiser Family members Foundation. You can view the complete Kaiser Daily Health Plan Record, search the archives, or join email delivery of in-depth coverage of health policy developments, discussions and debates.Augmentation of Rpe65 in animal models of Rpe65 deficiency can improve retinal and visual function, as assessed by means of electroretinography and observation of vision-guided behavior, respectively.4-6 We among others have previously reported that gene-augmentation therapy for RPE65 deficiency may improve areas of sight in individual participants.7-10 However, the magnitude and durability of benefit reported up to now in humans usually do not match those observed in animal models.11 Species-particular differences in the outcomes of gene therapy are largely unexplained, however they may reflect differences in pathophysiological mechanisms, vector tropism, or both.